Cancer-related CD15/FUT4 overexpression decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer.

J Exp Clin Cancer Res · 2015 · PMC4590269 · PMID 26427914

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Tumors displaying high CD15/FUT4 expression showed a trend towards: a) lower peritumoral immune-cells density and elevated NLR at diagnosis; b) poorer patients’ outcome both in terms of response to first line therapy and progression free survival (Fig. 1b-d and Additional file 3 : Figure S2C, D).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.